Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.
about
HSV-2: in pursuit of a vaccineUnderstanding natural herpes simplex virus immunity to inform next-generation vaccine designIdentification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.Detection of Diverse Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes in Peripheral Blood of Infected Persons by Screening for Responses to All Translated Proteins of HCVPhase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected SubjectsDiversity in CD8(+) T cell function and epitope breadth among persons with genital herpes.Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein BCD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes.Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpesClinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection.The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?Public TCR use by herpes simplex virus-2-specific human CD8 CTLs.A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigsTegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans.Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virusImmature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1.Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmissionProspects for control of herpes simplex virus disease through immunization.Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.Current status and prospects for development of an HSV vaccineRecent progress in herpes simplex virus immunobiology and vaccine researchCD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responsesDetection of antigen-specific cytotoxic T lymphocytes: significance for investigative dermatology.Expression of cutaneous lymphocyte-associated antigen and E-selectin ligand by circulating human memory CD4+ T lymphocytes specific for herpes simplex virus type 2.Homing in on the cellular immune response to HSV-2 in humans.Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virusClearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanismsMucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodesInduction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection.Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.Longitudinal analysis of herpes simplex virus-specific CD4+ cell clonotypes in infected tissues and bloodA single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
P2860
Q22306291-03B916C0-7946-4665-93DD-9352159C8F90Q26741484-330F3404-61BE-4525-AB2C-F58D5CCD7D48Q27303136-6BA88DC8-5F19-4282-8698-8EEE7968DD57Q27469764-42C60EAD-5300-4E76-B5F4-DD4A81CEDC9EQ27486108-0F18FAB6-3B69-4DA7-A566-971F0E61702EQ30496837-9D297984-9360-42F6-9314-6A6752DB4FABQ30576590-3B6727AF-3130-496C-B5D8-BCB1A106B9F9Q30847945-9E89D7AC-A5E8-44A4-94D8-9AD800C8DD35Q30957753-7491EA17-8E1F-4CDF-9E8E-FD477190C122Q31121774-5EA84122-9300-4FBF-87EB-9A77B85B8FBFQ33248961-ECC4F009-A911-4801-B449-681B6575897DQ33550768-9F359187-33D0-4125-A1D0-C078823562F7Q33611115-8E07CFEF-6B14-4913-B05A-D44E8784C1CBQ33625030-560D564C-A096-46AB-90E3-96CB10048340Q33653142-45EFA8BB-EEB3-4F7D-813C-57D5CC543FA8Q33662836-8A5281DB-A76E-4F4A-A723-8F024D58EA45Q33824488-AB5B64E8-9974-44EF-BC2A-21487D870AE2Q33825931-0F82BE68-A175-4006-98C6-FFB0FF95218AQ33826410-111C1862-B040-439C-8AE4-A896CAC72996Q33834517-4CFFA120-8F12-4F2A-9043-08583124A86AQ33842412-C1C5B213-6BD1-4F44-9F02-9B17D62E558BQ33843902-AE13A60B-B5CD-4163-8EAD-4B7107DDF663Q33850188-FF7126B6-1BE8-495F-969B-82A23640DB84Q33866424-DAA677BD-399A-42B6-A0E6-C073582D926CQ33881052-28675AC1-7185-4815-90F5-9FDA82F9267CQ33931016-703414B7-429D-4387-A5B8-CF6F69F0B9A6Q33963713-6B3736EB-27BA-4933-9397-AC863358DD0BQ33997723-D563F8E7-1726-4A1C-ABA2-4236F3BEB076Q34022532-23907F4A-B0AF-41CB-8DDF-EF265A1B10FAQ34081662-180E9F45-958F-4951-8262-F99BA17A72A2Q34081670-F8C68994-55A4-4AE0-A2AD-D96CF9B938BBQ34105712-1DF5DDA2-5CB2-47D9-B811-FD60ECC0F11DQ34142890-A17625C3-765B-47A3-96D6-6C1BF20E3910Q34279175-E0E55485-499F-4CA8-A043-5EABA30CF526Q34340988-B9487009-2482-475E-9FDD-F074E36FC880Q34343459-A86C7CC5-ED3C-48A3-8893-E7F10FA95AC4Q34350019-BC505218-619C-46D2-91EA-6CD0DF84261DQ34356255-0BEEC913-CF1D-409A-AB46-6C8C64FCAE0BQ34407213-74B7E721-1D59-4EBD-ABB1-45DD392A87FDQ34414463-22B6CAEF-AE97-427F-914C-28C9EFD03EB2
P2860
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@en
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@nl
type
label
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@en
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@nl
prefLabel
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@en
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@nl
P2093
P2860
P356
P1476
Clearance of HSV-2 from recurr ...... cific cytotoxic T lymphocytes.
@en
P2093
P2860
P304
P356
10.1172/JCI1758
P407
P577
1998-04-01T00:00:00Z